68 related articles for article (PubMed ID: 10368634)
1. Growth inhibition of nasopharyngeal carcinoma cells by EGF receptor tyrosine kinase inhibitors.
Sun Y; Fry DW; Vincent P; Nelson JM; Elliott W; Leopold WR
Anticancer Res; 1999; 19(2A):919-24. PubMed ID: 10368634
[TBL] [Abstract][Full Text] [Related]
2. Tyrosine kinase inhibitors. 14. Structure-activity relationships for methylamino-substituted derivatives of 4-[(3-bromophenyl)amino]-6-(methylamino)-pyrido[3,4-d]pyrimidine (PD 158780), a potent and specific inhibitor of the tyrosine kinase activity of receptors for the EGF family of growth factors.
Rewcastle GW; Murray DK; Elliott WL; Fry DW; Howard CT; Nelson JM; Roberts BJ; Vincent PW; Showalter HD; Winters RT; Denny WA
J Med Chem; 1998 Feb; 41(5):742-51. PubMed ID: 9513602
[TBL] [Abstract][Full Text] [Related]
3. Tyrosine kinase inhibitors. 13. Structure-activity relationships for soluble 7-substituted 4-[(3-bromophenyl)amino]pyrido[4,3-d]pyrimidines designed as inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor.
Thompson AM; Murray DK; Elliott WL; Fry DW; Nelson JA; Showalter HD; Roberts BJ; Vincent PW; Denny WA
J Med Chem; 1997 Nov; 40(24):3915-25. PubMed ID: 9397172
[TBL] [Abstract][Full Text] [Related]
4. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G
Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466
[TBL] [Abstract][Full Text] [Related]
5. In vivo toxicity, pharmacokinetics, and anticancer activity of Genistein linked to recombinant human epidermal growth factor.
Uckun FM; Narla RK; Zeren T; Yanishevski Y; Myers DE; Waurzyniak B; Ek O; Schneider E; Messinger Y; Chelstrom LM; Gunther R; Evans W
Clin Cancer Res; 1998 May; 4(5):1125-34. PubMed ID: 9607569
[TBL] [Abstract][Full Text] [Related]
6. Blockade of the epidermal growth factor receptor tyrosine kinase activity by quercetin and luteolin leads to growth inhibition and apoptosis of pancreatic tumor cells.
Lee LT; Huang YT; Hwang JJ; Lee PP; Ke FC; Nair MP; Kanadaswam C; Lee MT
Anticancer Res; 2002; 22(3):1615-27. PubMed ID: 12168845
[TBL] [Abstract][Full Text] [Related]
7. Inhibitors of epidermoid growth factor receptor suppress cell growth and enhance chemosensitivity of nasopharyngeal cancer cells in vitro.
Hsu CH; Gao M; Chen CL; Yeh PY; Cheng AL
Oncology; 2005; 68(4-6):538-47. PubMed ID: 16037687
[TBL] [Abstract][Full Text] [Related]
8. Tyrosine kinase inhibitors. 15. 4-(Phenylamino)quinazoline and 4-(phenylamino)pyrido[d]pyrimidine acrylamides as irreversible inhibitors of the ATP binding site of the epidermal growth factor receptor.
Smaill JB; Palmer BD; Rewcastle GW; Denny WA; McNamara DJ; Dobrusin EM; Bridges AJ; Zhou H; Showalter HD; Winters RT; Leopold WR; Fry DW; Nelson JM; Slintak V; Elliot WL; Roberts BJ; Vincent PW; Patmore SJ
J Med Chem; 1999 May; 42(10):1803-15. PubMed ID: 10346932
[TBL] [Abstract][Full Text] [Related]
9. Use of a pharmacophore model for the design of EGF-R tyrosine kinase inhibitors: 4-(phenylamino)pyrazolo[3,4-d]pyrimidines.
Traxler P; Bold G; Frei J; Lang M; Lydon N; Mett H; Buchdunger E; Meyer T; Mueller M; Furet P
J Med Chem; 1997 Oct; 40(22):3601-16. PubMed ID: 9357527
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of epidermal growth factor receptor activity by two pyrimidopyrimidine derivatives.
Solca FF; Baum A; Langkopf E; Dahmann G; Heider KH; Himmelsbach F; van Meel JC
J Pharmacol Exp Ther; 2004 Nov; 311(2):502-9. PubMed ID: 15199094
[TBL] [Abstract][Full Text] [Related]
11. Regeneration of human epidermis on acellular dermis is impeded by small-molecule inhibitors of EGF receptor tyrosine kinase.
Forsberg S; Ostman A; Rollman O
Arch Dermatol Res; 2008 Oct; 300(9):505-16. PubMed ID: 18446355
[TBL] [Abstract][Full Text] [Related]
12. Induction of heparin-binding EGF-like growth factor and activation of EGF receptor in imatinib mesylate-treated squamous carcinoma cells.
Johnson FM; Saigal B; Donato NJ
J Cell Physiol; 2005 Nov; 205(2):218-27. PubMed ID: 15887238
[TBL] [Abstract][Full Text] [Related]
13. Blockage of epidermal growth factor receptor by quinazoline tyrosine kinase inhibitors suppresses growth of human hepatocellular carcinoma.
Liu Y; Poon RT; Shao W; Sun X; Chen H; Kok TW; Fan ST
Cancer Lett; 2007 Apr; 248(1):32-40. PubMed ID: 16837130
[TBL] [Abstract][Full Text] [Related]
14. The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides.
Motoyama AB; Hynes NE; Lane HA
Cancer Res; 2002 Jun; 62(11):3151-8. PubMed ID: 12036928
[TBL] [Abstract][Full Text] [Related]
15. Cellular and in vivo activity of JNJ-28871063, a nonquinazoline pan-ErbB kinase inhibitor that crosses the blood-brain barrier and displays efficacy against intracranial tumors.
Emanuel SL; Hughes TV; Adams M; Rugg CA; Fuentes-Pesquera A; Connolly PJ; Pandey N; Moreno-Mazza S; Butler J; Borowski V; Middleton SA; Gruninger RH; Story JR; Napier C; Hollister B; Greenberger LM
Mol Pharmacol; 2008 Feb; 73(2):338-48. PubMed ID: 17975007
[TBL] [Abstract][Full Text] [Related]
16. The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: potential therapy for cancer.
Rusnak DW; Affleck K; Cockerill SG; Stubberfield C; Harris R; Page M; Smith KJ; Guntrip SB; Carter MC; Shaw RJ; Jowett A; Stables J; Topley P; Wood ER; Brignola PS; Kadwell SH; Reep BR; Mullin RJ; Alligood KJ; Keith BR; Crosby RM; Murray DM; Knight WB; Gilmer TM; Lackey K
Cancer Res; 2001 Oct; 61(19):7196-203. PubMed ID: 11585755
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice.
Pollack VA; Savage DM; Baker DA; Tsaparikos KE; Sloan DE; Moyer JD; Barbacci EG; Pustilnik LR; Smolarek TA; Davis JA; Vaidya MP; Arnold LD; Doty JL; Iwata KK; Morin MJ
J Pharmacol Exp Ther; 1999 Nov; 291(2):739-48. PubMed ID: 10525095
[TBL] [Abstract][Full Text] [Related]
18. Selective downregulation of EGF receptor and downstream MAPK pathway in human cancer cell lines by active components partially purified from the seeds of Livistona chinensis R. Brown.
Huang WC; Hsu RM; Chi LM; Leu YL; Chang YS; Yu JS
Cancer Lett; 2007 Apr; 248(1):137-46. PubMed ID: 16919867
[TBL] [Abstract][Full Text] [Related]
19. Antitumor activity of combined treatment of human cancer cells with ionizing radiation and anti-epidermal growth factor receptor monoclonal antibody C225 plus type I protein kinase A antisense oligonucleotide.
Bianco C; Bianco R; Tortora G; Damiano V; Guerrieri P; Montemaggi P; Mendelsohn J; De Placido S; Bianco AR; Ciardiello F
Clin Cancer Res; 2000 Nov; 6(11):4343-50. PubMed ID: 11106252
[TBL] [Abstract][Full Text] [Related]
20. Anticancer efficacy of the irreversible EGFr tyrosine kinase inhibitor PD 0169414 against human tumor xenografts.
Vincent PW; Bridges AJ; Dykes DJ; Fry DW; Leopold WR; Patmore SJ; Roberts BJ; Rose S; Sherwood V; Zhou H; Elliott WL
Cancer Chemother Pharmacol; 2000; 45(3):231-8. PubMed ID: 10663641
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
